NPCENasdaqSurgical & Medical Instruments & ApparatusFiscal year ends December 31
NeuroPace Inc
Financials through Q2 FY2026, quarter ended Jun 30, 2026Last filing: 10-Q on Aug 11, 2026
$12.77+0.53 (+4.33%)
Close on Oct 19, 2026
- Market cap
- $435.51M
- P/E (TTM)
- –
- Dividend yield
- 0.00%
NeuroPace statistics
Financials through Jun 30, 2026, price as of Oct 19, 2026, median of Surgical & Medical Instruments & Apparatus companies for comparison
Valuation
| Measure | NeuroPace | Industry median |
|---|---|---|
| Market Cap | $438.32M | $229.23M |
| Enterprise Value | $445.64M | $194.73M |
| PS Ratio | 4.43 | 3.14 |
| PB Ratio | 36.89 | 3.19 |
| P/TBV Ratio | 36.89 | 4.69 |
Enterprise value
| Measure | NeuroPace | Industry median |
|---|---|---|
| EV / Sales | 4.51 | 2.93 |
Income (trailing twelve months)
| Measure | NeuroPace | Industry median |
|---|---|---|
| Revenue | $98.84M | $102.39M |
| Gross Profit | $78.70M | $60.36M |
| Operating Income | -$15.08M | -$4.31M |
| Net Income | -$19.11M | -$6.57M |
| EBITDA | -$15.08M | -$1.98M |
| EPS (Diluted) | -$0.57 | -$0.07 |
Margins
| Measure | NeuroPace | Industry median |
|---|---|---|
| Gross Margin | 79.6% | 55.1% |
| Operating Margin | -15.3% | -6.04% |
| Profit Margin | -19.3% | -10.5% |
| EBITDA Margin | -15.3% | -2.67% |
| FCF Margin | -11.7% | -0.30% |
Returns
| Measure | NeuroPace | Industry median |
|---|---|---|
| Return on Equity (ROE) | -122.1% | -19.2% |
| Return on Assets (ROA) | -18.8% | -13.3% |
| Return on Invested Capital (ROIC) | -67.8% | -4.11% |
| Return on Capital Employed (ROCE) | -19.0% | -9.07% |
Growth
| Measure | NeuroPace | Industry median |
|---|---|---|
| Revenue Growth (YoY) | 16.9% | 8.85% |
| Revenue Growth (3Y CAGR) | 30.0% | 7.08% |
| Revenue Growth (5Y CAGR) | 19.4% | 11.8% |
Balance sheet
| Measure | NeuroPace | Industry median |
|---|---|---|
| Cash & Short-Term Investments | $51.70M | $37.33M |
| Total Debt | $59.01M | $72.66M |
| Net Cash (Debt) | -$7.31M | $3.92M |
| Net Cash Per Share | -$0.21 | $0.28 |
| Equity (Book Value) | $11.88M | $57.36M |
| Book Value Per Share | $0.35 | $2.81 |
| Tangible Book Value | $11.88M | $10.71M |
| Working Capital | $68.76M | $54.64M |
Financial position
| Measure | NeuroPace | Industry median |
|---|---|---|
| Current Ratio | 4.94 | 2.50 |
| Quick Ratio | 3.82 | 1.54 |
| Debt / Equity | 4.97 | 0.38 |
| Interest Coverage | -2.39 | -1.81 |
Cash flow (trailing twelve months)
| Measure | NeuroPace | Industry median |
|---|---|---|
| Operating Cash Flow | -$11.24M | -$653.46K |
| Capital Expenditures | -$369.00K | -$3.69M |
| Free Cash Flow | -$11.61M | -$835.02K |
| FCF Per Share | -$0.34 | -$0.02 |
Efficiency
| Measure | NeuroPace | Industry median |
|---|---|---|
| Asset Turnover | 0.97 | 0.59 |
| Inventory Turnover | 1.17 | 2.21 |
| Revenue Per Employee | $472.90K | $322.75K |
| Profits Per Employee | -$91.45K | -$52.11K |
| Employee Count | 209 | 197 |
Dividends and yields
| Measure | NeuroPace | Industry median |
|---|---|---|
| Earnings Yield | -4.36% | -6.92% |
| FCF Yield | -2.65% | -0.62% |
| Dividend Yield | 0.00% | 0.81% |
| Buyback Yield | 0.00% | 0.78% |
| Shareholder Yield | 0.00% | 0.84% |
| Dividend Per Share | $0.00 | $0.72 |
| Years of Dividend Growth | 0 | 0 |
Shares
| Measure | NeuroPace | Industry median |
|---|---|---|
| Shares Outstanding | 34,324,300 | 44,856,700 |
| Shares Change (YoY) | 8.60% | 3.35% |
| Shares Change (QoQ) | 1.10% | 0.27% |
| Float | 28,614,800 | 36,934,400 |
| Shares Held by Insiders | 16.6% | 10.6% |
| Shares Held by Institutions | 77.4% | 63.5% |
Scores
| Measure | NeuroPace | Industry median |
|---|---|---|
| Altman Z-Score | -3.71 | 1.95 |
| Piotroski F-Score | 5 | 5 |
Calculated by StockData from NeuroPace's SEC filings and the latest closing price. Hover a measure to see its formula. The grey column is the median of companies in the same industry group (two-digit SIC code); green or red marks a better or worse value than that median.